

## Webinar: Enabling a Step Change in Pharma Productivity (June 1, 2023)

### Frequently Asked Questions

**Q: Will AspenTech be embedding software solutions in Emerson's DeltaV?**

A: This is being actively considered where it makes sense. For example, from version 15 of DeltaV it is possible to deploy an Aspen Unscrambler model directly in DeltaV to enhance real-time quality assurance.

**Q: What do AspenTech and Emerson consider to be the top three most promising digitalization initiatives for pharma?**

A: Together, Emerson and AspenTech provide digital accelerators for the entire pharma product lifecycle. Three powerful examples are process analytical technology combined with excellent process controls to boost quality and yield; predictive and prescriptive maintenance to minimize unplanned downtime; and planning and scheduling to drive efficient, on-time product delivery.

**Q: How are AspenTech and Emerson addressing areas where they have competing software solutions? E.g., Syncade and APEM, or RTMS and Aspen Plant Scheduler™?**

A: Each customer's situation is unique and so the combined Emerson and AspenTech team will work with the customer to determine which solution is the best fit for their situation.

**Q: How will Emerson and AspenTech address customers that have both the AspenTech and Emerson solution (say at different sites) for a particular application area?**

A: Each customer has their own unique considerations on how to deploy a blend of both the Emerson and the AspenTech products. AspenTech and Emerson will continue to help guide and support customer's technologies and related decisions.

**Q: Will Inmation remain vendor agnostic now that AspenTech has acquired it?**

A: Inmation's wide applicability to all combinations of vendor solutions at any given site remains a core strength of this advanced data integration system. This openness will absolutely be maintained and enhanced by AspenTech going forward.

**Q: Will Emerson and AspenTech consider other strategic acquisitions together?**

A: Yes. Just as this remains a growth strategy for Emerson and AspenTech individually, the two companies can now collaborate on what strategic acquisitions are mutually beneficial going forward.

**Q: What are the top reasons that Life Sciences customers hesitate or delay making progress on the maturity model or Pharm 4.0 journey?**

A: Organizational change management can be a challenge, especially in cases where an organization clings to the mantra that "we have always done it this way." Additionally, some organizations are very reluctant to explain changes to a regulatory body. Regulatory bodies are encouraging organizations to adopt new technologies and are even establishing new programs to facilitate adoption in the industry, yet these authorities are responsible to ensure public safety, so Life Sciences organizations probably still feel some of that intrinsic tension.

**Q: What percent of Pharma could be using PAT (Process Analytical Technology) feedback control?**

A: PAT is applicable across the pharma product lifecycle: process design & optimization, tech transfer/scale-up, commercial manufacturing and real-time testing/product release. However, the highest rate of adoption is currently in product development. It is likely we will continue to see PAT adoption expand downstream as more companies implement continuous manufacturing.